← Eichor
Study identifier: NCT07173062 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Algae Effects in Markers of Cardiovascular Risk and Gut Microbiome

Condition: Stroke · Coronary Arterial Disease (CAD) · Myocardial Infarction (MI)  ·  Sponsor: Universidade do Porto

PhaseNA
Planned participants150
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersNo

About this study

The Western diet, rich in fat and sugar, contributes to cardiovascular risk and alters the body metabolism, specifically through the modulation of the microbiome. Microbiome is considered the "second genome", functioning as an endocrine-like organ. Gut microbiota-derived metabolites, namely trimethylamine- N-oxide and short-chain fatty acids have been associated with atherosclerosis, vascular and cardiac diseases. Regarding trimethylamine- N-oxide, its association with cardiovascular disease is positive and dose-dependent. In contrast, short-chain fatty acids have been positively associated with the improvement of cardiovascular health. Algae probiotics can modulate gut microbiome, stimulating the growth of commensal micro-organisms with health benefits. Previous studies suggested that Spirulina Arthrospira platensis supplementation could improve blood lipid levels and lower blood pressure, revealing anti-inflammatory and antioxidant roles. Other probiotics that could be beneficial to gut microbiota are macroalgae or seaweed. Macroalgae are a rich source of components which may prompt bacterial diversity and abundance. The present prospective, randomized, three-armed parallel trial aims to generate good-quality evidence about the potential health effects and impact of Spirulina Arthrospira platensis (microalgae) and Gelidium corneum (macroalgae) supplements in humans. These participants will undergo 3 clinical evaluations: 2 before the beginning of micro- and macro-algae su…

This description comes directly from the study's public registry record.

Talk to the study team

Francisca Saraiva, PhD  ·  220426820  ·  f.saraiva@med.up.pt

Janete Santos, PhD  ·  961239890  ·  investigaclinica@med.up.pt

Always discuss trial participation with your own doctor first.

Locations (1)

Unidade Local de Saúde de São JoãoPorto, PortugalRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07173062